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APP Expression in Primary 
Neuronal Cell Culturesfrom 
P6 Mice during in vitro 
Differentiation 
KeyWords Abstract 
Alzheimer's disease Primary neuronal cell cultures from P6 mice were investigated in order to 
Amyloid protein precursor study amyloid protein precursor (APP) gene expression in differentiating neu-
Cerebellar neurons rons. Cerebellar granule cells which strongly express APP 695 allowed the 
Sialic acid identification of three distinct isoforms of neuronal APP 695. The high-molec-
ular-weight form of APP 695 is sialylated. The expression pattern of neuronal 
APP 695 changes during in vitro differentiation. Sialylated forms become 
more abundant upon longer cultivation time. The secreted forms of sialylated, 
neuronal APP 695 are shown to comigrate with APP isolated from cerebrospi-
nal fluid. We suggest that the different sialylation states of APP 695 may 
reflect the modulation of cell-cell and cell-substrate interactions during in 
vitro differentiation and regeneration. 
Introduction 
Alzheimer's disease (AD) is a neurodegenerative disor-
der characterized by intracellular neurofibrillary tangles, 
extracellular plaques and cerebrovascular amyloid in the 
brains of affected individuals. The principal component 
of the deposits is the ßA4 protein, which is derived from a 
larger amyloid protein precursor (APP) [1]. Several alter-
native splice forms of this membrane-spanning glycopro-
tein have been identified so far [2-7]. As shown by differ-
ent authors, APP 695 is the predominantly expressed 
form in the developing central nervous System, whereas 
peripheral tissues mainly express the KPI-containing 
APPs [4, 6, 8-11]. Biochemical analyses have shown that 
APP is posttranslationaly modified by N - and O-glycosy-
lation as well as tyrosine sulfation and serine phosphory-
lation [12, 13]. Proteolytic cleavage within the amyloido-
genic region leads to secretion of a large soluble NH2-
terminal APP fragment into the surrounding environment 
[12, 14, 15]. Such carboxyl-terminal truncated molecules 
are found in cerebrospinal fluid (CSF) and blood [12, 16, 
17]. APPs circulating in blood are mainly derived from 
APP 751 and 770. They may be secreted by platelets and 
leukocytes and were shown to be identical with protease 
nexin 2 [18-21]. In contrast, soluble APP found in CSF 
mainly lacks the KPI insert, reflecting the predominant 
expression of APP 695 in the central nervous System. 
It has been suggested by several authors that APP 695 
plays an important role in neuronal differentiation and 
regeneration [22-24]. 
Cerebellar cells derived from early postnatal brain 
share many of the features characteristic for their counter-
Accepted: U. Mönning © 1993 S. Karger AG, Basel 
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parts in vivo such as cell migration, axonal sprouting, Syn-
apse formation and electric activity [25-28]. Thus they 
provide an ideal model for investigating APP biosynthesis 
during differentiation processes and formation of neuro-
nal networks. Using this approach, we have studied the 
biogenesis of APP in developing neurons. Our findings 
show that APP is indeed strongly expressed by neuronal 
cells. Differentiation of these cells in vitro was associated 
with changes in posttranslational modification of amyloid 
protein precursor. 
Materials and Methods 
C e l l C u l t u r e 
The cell culture protocol employed was a modification of the 
methods described by Schnitzer et al. [29]. 
Cerebelli were obtained from postnatal Balb/c mice (P6). At this 
stage of development, granule cells constitute approximately 90% of 
all cerebellar neurons [30]. After removal of the meninges, cerebelli 
were incubated for 15 min in a Solution of 10 mg/ml trypsin in C a 2 + -
and Mg 2 +-containing Hanks balanced salt Solution (HBSS +). Cerebel-
l i were rinsed three times in C a 2 + - and Mg2 +-free HBSS, followed by 
dissociation of the cells. This was done in 0.5 mg/ml DNAse I in 
HBSS + by trituration through the narrowed bore of a fire-polished 
Pasteur pipette. Cells were distributed to polylysine-coated (100 u-g/ 
ml) culture dishes containing 2 ml of Earl's Basal Medium (BME; 
Gibco) buffered with sodium bicarbonate (10 mA/) and supple-
mented with 10% horse serum (Gibco). Neurons were plated at a 
density of about 5 x 104 cells/cm 2. Cultures were maintained in a 
humified incubator at 37°C in 5% C 0 2 . 
I m munocy löchern istry 
Coverslips were removed from culture dishes, briefly rinsed with 
phosphate-buffered saline (PBS; p H 7.2) and fixed with freshly pre-
pared 4% paraformaldehyde (in PBS; pH 7.2) at room temperature 
for 15 min. After permeabilization with 0.3% TX-100 in PBS for 5 
min, nonspecific binding sites were blocked with 1 % human serum 
albumin, 10% FCS in PBS for 30 min at room temperature (RT). 
Cells were then incubated with primary antibodies in PBS (0.3% T X -
100, 1% human serum albumin) at 4 ° C overnight, extensively 
washed with PBS and incubated with fluorescein- and rhodamine-
conjugated secondary antibodies for 1 h at RT. Coverslips were 
washed for 45 min in PBS before being mounted upside down on a 
drop of aqueous mounting medium (Moviol including 2.5% D A B -
CO). Cells were examined on a Zeiss axioplan microscope equipped 
with phase contrast and epifluorescence optics for rhodamine and 
fluorescein. 
Antibodies were used at the following dilutions: polyclonal anti-
Fd-APP [12], 1:400; monoclonal anti-GFAP (Serva), 1:50; mono-
clonal anti-neurofilament (Dakopatts), 1:50; fluorescein-conjugated 
goat anti-rabbit (Sigma) 1:100; rhodamine-conjugated goat anti-
mouse (Jackson), 1:100. 
Biosynthetic L a b e l i n g 
After removal of the culture medium, cells were radioactively 
labeled with 120 uCi of [35S]methionine (Amersham) in 1.5 ml of 
methionine-free Dulbecco's modified Eagle's medium (DMEM) for 
4 h. The conditioned medium was then cleared by centrifugation and 
stored at -20 °C. Cells were washed once with phosphate-buffered 
saline. For lysis, cells were resuspended in 0.2 ml of lysis buffer 
[50 m M Tris, p H 7.5, 150 m M NaCl , 2 m M E D T A , 1% Nonidet 
P-40, 1% Triton X-100. 2 m M phenylmethanesulfonylfluoride 
(PMSF), 10 (ig/ml aprotinin, 10 ug/ml leupeptin and 1.6 mg/ml io-
doacetamide] and incubated for 30 min on ice. Cell lysates were cen-
trifuged at 10,000 g for 5 min, and the supernatants were stored at 
- 2 0 ° C until further use. The extraction pellet was discarded. 
I m m unoprecipitation 
For immunoprecipitation of [35S]methionine-labeled APP, 100 ul 
of cell lysate or 750 ul of conditioned medium were used. The cell 
lysate was diluted 1:1 with ice-cooled washing buffer B (20 mA/Tris, 
pH 7.5, 500 m A / N a C l , 0.5% Nonidet P-40, 2 m M PMSF). Lysate 
was preincubated for 2 h at room temperature with 10 ul of preim-
mune serum and 3 mg of protein A-Sepharose. Insoluble complexes 
were spinned down and discarded. The supernatants were incubated 
for 1 h at room temperature with 5 ul of undiluted anti-CT or anti-
FdAPP. The polyclonal anti-CT antiserum was raised against a syn-
thetic peptide, which corresponds to the COOH-terminal 43 residues 
of APP . Polyclonal anti-FdAPP antiserum was raised against puri-
fied Escherichia coli FdAPP fusion protein consisting of A P P 695 
and the Fd fragment of the murine IgM heavy chain [12]. 
After addition of 2 mg of protein A-Sepharose, the mixture was 
incubated for 30 min at RT. Nonbound proteins were removed from 
Sepharose beads by sequential washing with buffer A (20 mAf Tris, 
p H 7.5, 150 m M NaCl , 0.4% Nonidet P-40, 0.4% Triton X-100, 
2 m M PMSF), washing buffer B and fmally with TSA Solution (20 
m M Tris, p H 8.0, 150 m M NaCl). The immunoprecipitates were 
fractionated by SDS-PAGE (8%). Gels were soaked in enhancer Solu-
tion, dried and exposed to Kodak X - O M A T A R film at -70 °C. 
Secreted A P P was precipitated under nondetergent conditions 
and analyzed by subsequent immunoblotting. Immunoblotting was 
performed as described by Mönning et al. [34]. 
Enzymatic Digestion 
Prior to enzymatic digestion with neuraminidase from Clostrid-
i u m perfringens (Sigma), immunoprecipitated proteins were denatu-
rated in 20 ul of 0.2% SDS, 2% M C E for 10 min at 100°C followed 
by addition of 100 ul of sodium-acetate buffer (pH 6.0; 100 m M ) . 
Enzymatic digestion was performed with 10 m U of neuraminidase at 
37 ° C for 16 h. The proteins were dried and resuspended in Laemmli 
sample buffer. After boiling, labeled proteins were subjected to SDS-
P A G E . 
Results 
I m m u n o c y t o c h e m i s t r y 
For immunocytochemical localization of APP in pri-
mary neuronal cell culture, cerebellar cells from P6 mice 
were isolated and grown on poly-l-lysine-coated coverslips 
in the presence of 10% horse serum. Medium was not 
changed until cells were used for staining procedure, 
usually carried out after six days of cultivation. Staining 
302 Dichgans/Mönning/König/Sandbrink/ Biosynthesis of A P P in Cerebellar Neurons 
Masters/Beyreuther 
Fig. 1. [ndirect immunofluorescence of 
primary cerebellar cell cullures. Cells were 
obtained from P6 mice and cultivated for 6 
days. a Phase contrast. b Immunostaining 
with polyclonal anti-FdAPP serum. APP im-
munoreactivity is detected in granulär cells. 
c/d Double staining with anti-Fd APP serum 
(c) and (d) monoclonal anti-GFAP (d). Neu-
rons are the main source of APP-immunore-
activity (c). Astroglia, identified by G F A P -
slaining (d) show a weak APP staining. 
with polyclonal anti-Fd-APP showed an intense labeling 
of granulär cells which represented about 90% of cells in 
culture (fig. la , b). Within these neurons, strong A P P 
reactivity could be detected close to the nucleus at a some-
what excentric Position. Double staining with an t i -GFAP 
(glial fibrillary acidic protein) revealed only weak labeling 
of astroglia (fig. lc , d). Fibroblasts and Oligodendroglia, as 
identified by their morphology, also showed low A P P 
reactivity (results not shown). Thus, under our in vitro 
conditions granulär cells were the main source of A P P . 
M e t a b o l i e C h a r a c t e r i z a t i o n 
In order to analyze A P P expression within these cells 
proteins were metabolically labeled with [ 3 5S]-methio-
nine and immunopreeipitated with anti-CT, an antise-
rum raised against the synthetic cytoplasmic part of 
A P P . As shown in figure 2a, three distinet bands with a 
molecular weight of approximately 102, 112 and 120 k D 
could be detected in detergent extracts from cell pellets. 
They correspond to translation produets of A P P 695 
m R N A as was confirmed by R N A analysis (results not 
shown). These findings are in aecordance with results 
303 
C e r e b e l l a r neurons C S F 
a b c 
kD kD 
- 180 -
Ce l l lysate C o n d i t i o n e d 
m e d i u m 
Fig. 2. Analysis of A P P biosynthesis of cerebellar neurons. 
a Immunoprecipitation of A P P from [35S]methionine-labeled cell 
lysate of cerebellar neurons. Biosynthetic labeling was performed 
after 6 days of cultivation. The immunoprecipitates were analysed by 
autoradiography. Precipitation was done with the polyclonal anti-CT 
antiserum. b Identification of secretory A P P from cerebellar neurons 
cultivated for 6 days. Conditioned medium of neurons was subjected 
to immunoprecipitation with anti-FdAPP serum. The immunopre-
cipitates were analyzed by immunoblotting. Detection of A P P was 
performed with the monclonal antibody 22C11. c Western Blot anal-
ysis of A P P from cerebrospinal fluid. Detection of A P P was done as 
described in b. 
from other groups who were able to show, that APP 695 
is the predominantly expressed form in neurons [3, 4, 6, 
8, 9,31]. 
For detection of secretory APP released by neuronal 
cells, conditioned medium was investigated. Since poly-
clonal anti-Fd APP did not precipitate soluble isoforms of 
mouse APP under high detergent concentrations neces-
sary for radioactive immunoprecipitations followed by 
autoradiography, secretory APP was identified by West-
ern blot analysis with monoclonal 22C11. Two immuno-
reactive bands with an apparent molecular mass of 95 and 
105 kD were identified (fig. 2b). The upper band of secre-
tory APP was shown to comigrate with APP derived from 
cerebrospinal fluid (fig. 2c). 
In order to assess APP biosynthesis during differentia-
tion, cells were cultivated for different time periods (1,2, 
4, 6 and 9 days). At the end of each cultivation period, 
cells were metabolically labeled, immunoprecipitated 
with anti-CT and analyzed by SDS-PAGE. The autoradi-
ography of the cell lysates is shown in figure 3a. The densi-
tometric scanning analysis of the autoradiography is 
graphically demonstrated in figure 3b. At all time points 
investigated, cells in vitro expressed all three forms of 
APP 695. However, within prolonged cultivation time the 
ratio between these different forms changed. Whereas the 
lower band was dominating up to 48 h of cultivation, the 
higher molecular weight APP isoforms (112 kD and 120 
kD) became more prominent upon longer cultivation 
time. At day 9 in culture, cells expressed large amounts of 
the high-molecular weight APP isoforms. The amount of 
secretory APP remained unchanged over the whole time 
investigated (results not shown). 
P o s t t r a n s l a t i o n a l M o d i f i c a t i o n s 
As could be shown by different authors, APP is post-
translationaly modified by N - and O-glycosylation as well 
as tyrosine sulfation and serine phosphorylation [12, 13]. 
APP has been proposed to be a cell adhesion molecule 
involved in cell-cell and cell-substrate interactions [31-
34]. We have investigated whether neuronal APP is sialy-
lated since sialic acid residues are known to play a key role 
in adhesion processes mediated by molecules like N - C A M 
(neuronal cell adhesion molecule) [35-37]. 
Immunoprecipitated APP was enzymatically digested 
with neuraminidase from C l o s t r i d i u m perfringens prior to 
separating proteins on SDS-PAGE. As shown in figure 4, 
the high molecular weight APP isoform (120 kD) disap-
peared after treatment with neuraminidase. Concomitant 
with the decrease of cell-associated 120-kD APP isoform 
there was an increase in the amount of cell-associated 
112-kD APP. These experiments may indicate that the 
112-kD APP isoform is the nonsialylated precursor of the 
high-molecular-weight APP isoform (120 kD). Sialylation 
of the 112-kD form gives rise to the apparent molecular 
weight shift of approximately 8 kD resulting in high-
molecular-weight APP 695. 
Cell associated, sialylated APP 695 was less prominent 
after 24 h of cultivation (8% of total APP) but contributes 
to about 45% of total APP upon 9 days of in vitro cultiva-
tion. This indicates that sialylation of neuronal APP 695 
is regulated in a time-dependent way during in vitro dif-
ferentiation. 
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Fig. 3. Expression of A P P in cerebellar neurons during in vitro 
differentiation. a Cells were cultivated for different time periods. 
Biosynthetic labeling with [35S]methionine was done at times indi-
cated at the top of each lane. A P P was isolated from cell pellets by 
immunoprecipitation with anti-CT antiserum. The immunoprecipi-
tates were analyzed as in figure 2a. b Densitometrie quantitation of 
the A P P immunoprecipitation analysis (a) of cerebellar neurons cul-
tivated for different time periods. 
Fig. 4. Neuraminidase-treatment of cell-associated APP695 A P P 
was immunoprecipitated from radiolabeled detergent extracts of cer-
ebellar neurons with polyclonal anti-CT serum prior to enzymatic 
digestion with neuraminidase from Clostridium perfringens (Neu). 
Precipitates were analyzed by SDS-PAGE (8%) followed by autora-
diography (C, non-digested APP). 
Discussion 
Primary neuronal cell culture from P6 mice was inves-
tigated to gain insight into APP expression during neuro-
nal differentiation processes. Cerebellar neurons showed 
an intense labeling with anti-Fd APP, whereas astrocytes 
revealed only a weak APP immunoreactivity. This is in 
agreement with results from other groups, who have 
shown that neurons are the main source of cerebral APP 
produetion [10, 16, 31, 38, 39]. Large amounts of neuro-
nal APP are associated with the Golgi apparatus as 
revealed by light- and electron-microscopic immunocyto-
chemical techniques [39, 40]. Our data support these 
results since neuronal APP immunoreactivity was intra-
cellularly located proximal to the nucleus. Rapid turnover 
of transmembrane APP by cleavage within the ßA4 
sequence might explain the weak cell surface staining. 
This is evidenced by the fact that large amounts of secre-
tory APP could be detected already on day 1 in vitro. 
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We have shown that APP 695 from cerebellar neurons 
is posttranslationally modified by sialylation. Sialic acid 
residues are known to have great influence on adhesion 
properties of cell surface molecules. The best studied 
example is N - C A M (neuronal cell adhesion molecule) 
which exists in a highly sialylated form as well as several 
isoforms containing less sialic acid [41, 42]. The sialyla-
tion of N - C A M is developmentally regulated [43]. Poly-
sialylation of N - C A M is known to promote axonal 
branching and decrease cell adhesivity, whereas removal 
of polysialic acid increases axonal fasciculation [35-37]. 
APP was shown to be involved in cell-cell and cell-sub-
strate interactions [31-34]. We therefore suggest that sia-
lylation of APP 695 might be a mechanism by which neu-
ronal cell adhesion properties are modulated. Three dis-
tinct forms of neuronal APP 695 can be identified by 
Western blot analysis. The 120-kD APP isoform was 
shown to be sialylated. During in vitro differentiation, 
changes in the expression pattern of neuronal APP 695 
were observed. Sialylated APP was rarely detectable after 
cultivation for 24 h, but was increased up to 45% of total 
APP upon 9 days of cultivation. These changes could pro-
vide the basis for regulation of cell-cell and cell-substrate 
interactions during in vitro differentiation of cerebellar 
neurons. The sialylation State seems to depend upon the 
State of differentiation of the neurons investigated. The 
presence of polysialylated cell associated APP may be a 
requirement for axonal branching and cell migration 
whereas a low sialylation State may be necessary for axon-
al fasciculation and cell adhesion. 
We postulate that changes in the sialylation State of 
APP 695 play an important role in cellular interactions 
associated with neuronal cell migration and axonal guid-
ing during early postnatal brain development. APP could 
thus belong to the group of cell surface molecules which 
are involved in the establishment of the neuronal net-
work. 
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